Details of the Drug

General Information of Drug (ID: DMR2IQ4)

• Drug Name: Tizanidine
• Synonyms: Sirdalud; Ternelin; Tizanidina; Tizanidinum; Sirdalud (TN); Tizanidina [INN-Spanish]; Tizanidine (INN); Tizanidine [INN:BAN]; Tizanidinum [INN-Latin]; Zanaflex (TN); 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine

Indication

Disease Entry	ICD 11	Status	REF
Spasm	MB47.3	Approved	[1]

• Therapeutic Class: Analgesics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 253.71
  Logarithm of the Partition Coefficient (xlogp); 1.1
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2.5 hours []
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.36486 micromolar/kg/day [4]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.7% [3]
  Vd: The volume of distribution (Vd) of drug is 2.4 L/kg []
• Chemical Identifiers:
  Formula: C9H8ClN5S
  IUPAC Name: 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
  Canonical SMILES: C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
  InChI: InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
  InChIKey: XFYDIVBRZNQMJC-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5487
  ChEBI ID: CHEBI:63629
  CAS Number: 51322-75-9
  DrugBank ID: DB00697
  TTD ID: D01MDT
  INTEDE ID: DR1605
  ACDINA ID: D00682

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[6]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tizanidine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[7]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Idarubicin.	Acute myeloid leukaemia [2A60]	[8]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Arn-509.	Acute myeloid leukaemia [2A60]	[9]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[10]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Tizanidine and Oliceridine.	Acute pain [MG31]	[11]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Tizanidine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[12]
Metyrosine	DMBYCU0	Moderate	Additive CNS depression effects by the combination of Tizanidine and Metyrosine.	Adrenomedullary hyperfunction [5A75]	[12]
Mepyramine	DMB4SFH	Moderate	Additive CNS depression effects by the combination of Tizanidine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Phenyltoloxamine	DMKAEQW	Moderate	Additive CNS depression effects by the combination of Tizanidine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Tripelennamine	DMZBU15	Moderate	Additive CNS depression effects by the combination of Tizanidine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[12]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Rivastigmine.	Alzheimer disease [8A20]	[8]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Donepezil.	Alzheimer disease [8A20]	[8]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Tizanidine and Metronidazole.	Amoebiasis [1A36]	[14]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Ivabradine.	Angina pectoris [BA40]	[9]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Bepridil.	Angina pectoris [BA40]	[8]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Dronedarone.	Angina pectoris [BA40]	[8]
Methylphenobarbital	DMDSWAG	Moderate	Additive CNS depression effects by the combination of Tizanidine and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[13]
Chlormezanone	DMTWUXR	Moderate	Additive CNS depression effects by the combination of Tizanidine and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[12]
Oxazepam	DMXNZM4	Moderate	Additive CNS depression effects by the combination of Tizanidine and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[12]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Cilostazol.	Arterial occlusive disease [BD40]	[8]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Posaconazole.	Aspergillosis [1F20]	[8]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Levalbuterol.	Asthma [CA23]	[15]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Terbutaline.	Asthma [CA23]	[16]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Pirbuterol.	Asthma [CA23]	[16]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Salbutamol.	Asthma [CA23]	[15]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Formoterol.	Asthma [CA23]	[16]
Zileuton	DMVRIC2	Major	Decreased metabolism of Tizanidine caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[17]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[9]
Desipramine	DMT2FDC	Moderate	Additive CNS depression effects by the combination of Tizanidine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[12]
Obeticholic acid	DM3Q1SM	Major	Decreased metabolism of Tizanidine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[17]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[8]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Tizanidine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[8]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Major	Decreased metabolism of Tizanidine caused by Norfloxacin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[8]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[8]
Retigabine	DMGNYIH	Moderate	Additive CNS depression effects by the combination of Tizanidine and Retigabine.	Behcet disease [4A62]	[12]
Cariprazine	DMJYDVK	Moderate	Additive CNS depression effects by the combination of Tizanidine and Cariprazine.	Bipolar disorder [6A60]	[12]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Tizanidine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[19]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Tizanidine and Loperamide.	Bowel habit change [ME05]	[12]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Eribulin.	Breast cancer [2C60-2C6Y]	[8]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Lapatinib.	Breast cancer [2C60-2C6Y]	[8]
Niclosamide	DMJAGXQ	Major	Decreased metabolism of Tizanidine caused by Niclosamide mediated inhibition of CYP450 enzyme.	Cestodes infection [1F70-1F76]	[17]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[20]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[15]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Levetiracetam	DMTGDN8	Moderate	Additive CNS depression effects by the combination of Tizanidine and Levetiracetam.	Chronic pain [MG30]	[12]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Isoproterenol.	Conduction disorder [BC63]	[15]
Azelastine	DMXTMBJ	Moderate	Additive CNS depression effects by the combination of Tizanidine and Azelastine.	Conjunctiva disorder [9A60]	[13]
Drospirenone	DM1A9W3	Major	Decreased metabolism of Tizanidine caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[21]
Norgestimate	DMYP4XC	Major	Decreased metabolism of Tizanidine caused by Norgestimate mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[21]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Halothane.	Corneal disease [9A76-9A78]	[8]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Propofol.	Corneal disease [9A76-9A78]	[22]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Sevoflurane.	Corneal disease [9A76-9A78]	[8]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Tizanidine and Alfentanil.	Corneal disease [9A76-9A78]	[11]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Tizanidine and Remifentanil.	Corneal disease [9A76-9A78]	[11]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Probucol.	Coronary atherosclerosis [BA80]	[8]
Benzonatate	DM9U4FO	Moderate	Additive CNS depression effects by the combination of Tizanidine and Benzonatate.	Cough [MD12]	[12]
Chlophedianol	DMXGJEI	Moderate	Additive CNS depression effects by the combination of Tizanidine and Chlophedianol.	Cough [MD12]	[13]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Clofazimine.	Crohn disease [DD70]	[23]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Mifepristone.	Cushing syndrome [5A70]	[8]
Osilodrostat	DMIJC9X	Major	Decreased metabolism of Tizanidine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[17]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Tizanidine and Ethanol.	Cystitis [GC00]	[12]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Sertraline.	Depression [6A70-6A7Z]	[8]
Trimipramine	DM1SC8M	Moderate	Additive CNS depression effects by the combination of Tizanidine and Trimipramine.	Depression [6A70-6A7Z]	[12]
Cyclobenzaprine	DM1YBRM	Moderate	Additive CNS depression effects by the combination of Tizanidine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[12]
Nefazodone	DM4ZS8M	Moderate	Additive CNS depression effects by the combination of Tizanidine and Nefazodone.	Depression [6A70-6A7Z]	[12]
Paroxetine	DM5PVQE	Moderate	Additive CNS depression effects by the combination of Tizanidine and Paroxetine.	Depression [6A70-6A7Z]	[12]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Tizanidine and Isocarboxazid.	Depression [6A70-6A7Z]	[12]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Escitalopram.	Depression [6A70-6A7Z]	[8]
Tranylcypromine	DMGB5RE	Moderate	Additive CNS depression effects by the combination of Tizanidine and Tranylcypromine.	Depression [6A70-6A7Z]	[12]
Desvenlafaxine	DMHD4PE	Moderate	Additive CNS depression effects by the combination of Tizanidine and Desvenlafaxine.	Depression [6A70-6A7Z]	[12]
OPC-34712	DMHG57U	Moderate	Additive CNS depression effects by the combination of Tizanidine and OPC-34712.	Depression [6A70-6A7Z]	[12]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Tizanidine and Phenelzine.	Depression [6A70-6A7Z]	[12]
Clomipramine	DMINRKW	Moderate	Additive CNS depression effects by the combination of Tizanidine and Clomipramine.	Depression [6A70-6A7Z]	[12]
Doxepin	DMPI98T	Moderate	Additive CNS depression effects by the combination of Tizanidine and Doxepin.	Depression [6A70-6A7Z]	[12]
Maprotiline	DMPWB7T	Moderate	Additive CNS depression effects by the combination of Tizanidine and Maprotiline.	Depression [6A70-6A7Z]	[12]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Tizanidine and Esketamine.	Depression [6A70-6A7Z]	[12]
Heroin diacetylmorphine	DMDBWHY	Moderate	Additive CNS depression effects by the combination of Tizanidine and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[13]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[8]
Meclizine	DMS7T13	Moderate	Additive CNS depression effects by the combination of Tizanidine and Meclizine.	Dizziness and giddiness [MB48]	[12]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Deutetrabenazine.	Dystonic disorder [8A02]	[24]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Ingrezza.	Dystonic disorder [8A02]	[25]
Oestradiol valerate and dienogest	DMZK0FQ	Major	Decreased metabolism of Tizanidine caused by Oestradiol valerate and dienogest mediated inhibition of CYP450 enzyme.	Endometriosis [GA10]	[21]
Diazepam	DM08E9O	Moderate	Additive CNS depression effects by the combination of Tizanidine and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[12]
Zonisamide	DM0DTF7	Moderate	Additive CNS depression effects by the combination of Tizanidine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[12]
Oxcarbazepine	DM5PU6O	Moderate	Additive CNS depression effects by the combination of Tizanidine and Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[12]
Methsuximide	DM6L5VO	Moderate	Additive CNS depression effects by the combination of Tizanidine and Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[12]
Gabapentin	DM6T924	Moderate	Additive CNS depression effects by the combination of Tizanidine and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[12]
Cenobamate	DM8KLU9	Moderate	Additive CNS depression effects by the combination of Tizanidine and Cenobamate.	Epilepsy/seizure [8A61-8A6Z]	[12]
Tiagabine	DMKSQG0	Moderate	Additive CNS depression effects by the combination of Tizanidine and Tiagabine.	Epilepsy/seizure [8A61-8A6Z]	[12]
Stiripentol	DMMSDOY	Moderate	Additive CNS depression effects by the combination of Tizanidine and Stiripentol.	Epilepsy/seizure [8A61-8A6Z]	[12]
Phenacemide	DMOHS9P	Moderate	Additive CNS depression effects by the combination of Tizanidine and Phenacemide.	Epilepsy/seizure [8A61-8A6Z]	[12]
Brivaracetam	DMSEPK8	Moderate	Additive CNS depression effects by the combination of Tizanidine and Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[12]
Clonazepam	DMTO13J	Moderate	Additive CNS depression effects by the combination of Tizanidine and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[12]
Lacosamide	DMVM6QR	Moderate	Additive CNS depression effects by the combination of Tizanidine and Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[12]
Rufinamide	DMWE60C	Moderate	Additive CNS depression effects by the combination of Tizanidine and Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[12]
Phenobarbital	DMXZOCG	Moderate	Additive CNS depression effects by the combination of Tizanidine and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[12]
Vigabatrin	DMYT0OG	Moderate	Additive CNS depression effects by the combination of Tizanidine and Vigabatrin.	Epilepsy/seizure [8A61-8A6Z]	[12]
Eslicarbazepine	DMZREFQ	Moderate	Additive CNS depression effects by the combination of Tizanidine and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[12]
Cannabidiol	DM0659E	Moderate	Additive CNS depression effects by the combination of Tizanidine and Cannabidiol.	Epileptic encephalopathy [8A62]	[12]
Diphenhydramine	DMKQTBA	Moderate	Additive CNS depression effects by the combination of Tizanidine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[12]
Dantrolene	DM1D8XY	Moderate	Additive CNS depression effects by the combination of Tizanidine and Dantrolene.	Fever [MG26]	[12]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Solifenacin.	Functional bladder disorder [GC50]	[8]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Pentamidine.	Fungal infection [1F29-1F2F]	[8]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Ketoconazole.	Fungal infection [1F29-1F2F]	[8]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[8]
Acetazolamide	DM1AF5U	Moderate	Additive CNS depression effects by the combination of Tizanidine and Acetazolamide.	Glaucoma [9C61]	[12]
Methazolamide	DM7J2TA	Moderate	Additive CNS depression effects by the combination of Tizanidine and Methazolamide.	Glaucoma [9C61]	[12]
Dichlorphenamide	DMH7IDQ	Moderate	Additive CNS depression effects by the combination of Tizanidine and Dichlorphenamide.	Glaucoma [9C61]	[13]
Isoniazid	DM5JVS3	Major	Decreased metabolism of Tizanidine caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[17]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Tizanidine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[26]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Tizanidine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[29]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Tizanidine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[8]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Tizanidine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[30]
Givosiran	DM5PFIJ	Major	Decreased metabolism of Tizanidine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[17]
Belladonna	DM2RBWK	Moderate	Additive CNS depression effects by the combination of Tizanidine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[12]
Suvorexant	DM0E6S3	Moderate	Additive CNS depression effects by the combination of Tizanidine and Suvorexant.	Insomnia [7A00-7A0Z]	[12]
Amobarbital	DM0GQ8N	Moderate	Additive CNS depression effects by the combination of Tizanidine and Amobarbital.	Insomnia [7A00-7A0Z]	[12]
Ramelteon	DM7IW9J	Moderate	Additive CNS depression effects by the combination of Tizanidine and Ramelteon.	Insomnia [7A00-7A0Z]	[12]
Triazolam	DMETYK5	Moderate	Additive CNS depression effects by the combination of Tizanidine and Triazolam.	Insomnia [7A00-7A0Z]	[12]
Zaleplon	DMGFWSM	Moderate	Additive CNS depression effects by the combination of Tizanidine and Zaleplon.	Insomnia [7A00-7A0Z]	[12]
Propiomazine	DMKY8V1	Moderate	Additive CNS depression effects by the combination of Tizanidine and Propiomazine.	Insomnia [7A00-7A0Z]	[12]
Tasimelteon	DMLOQ1V	Moderate	Additive CNS depression effects by the combination of Tizanidine and Tasimelteon.	Insomnia [7A00-7A0Z]	[12]
Paraldehyde	DMOC1BX	Moderate	Additive CNS depression effects by the combination of Tizanidine and Paraldehyde.	Insomnia [7A00-7A0Z]	[12]
Quazepam	DMY4D87	Moderate	Additive CNS depression effects by the combination of Tizanidine and Quazepam.	Insomnia [7A00-7A0Z]	[12]
Estazolam	DMZGXUM	Moderate	Additive CNS depression effects by the combination of Tizanidine and Estazolam.	Insomnia [7A00-7A0Z]	[12]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[9]
Dicyclomine	DMZSDGX	Moderate	Additive CNS depression effects by the combination of Tizanidine and Dicyclomine.	Irritable bowel syndrome [DD91]	[12]
Remimazolam	DMLVSYX	Moderate	Additive CNS depression effects by the combination of Tizanidine and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[12]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Crizotinib.	Lung cancer [2C25]	[31]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Ceritinib.	Lung cancer [2C25]	[8]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Tizanidine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[32]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Tizanidine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[17]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Selpercatinib.	Lung cancer [2C25]	[9]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Lumefantrine.	Malaria [1F40-1F45]	[14]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Halofantrine.	Malaria [1F40-1F45]	[33]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Hydroxychloroquine.	Malaria [1F40-1F45]	[34]
Primaquine	DMWQ16I	Major	Decreased metabolism of Tizanidine caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[17]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[9]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Tizanidine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[35]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Tizanidine and Idelalisib.	Mature B-cell leukaemia [2A82]	[36]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[37]
Vemurafenib	DM62UG5	Major	Decreased metabolism of Tizanidine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[17]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and LGX818.	Melanoma [2C30]	[38]
Ethinyl estradiol	DMODJ40	Major	Decreased metabolism of Tizanidine caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[21]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Tizanidine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[39]
Almogran	DM7I64Z	Moderate	Additive CNS depression effects by the combination of Tizanidine and Almogran.	Migraine [8A80]	[12]
Frovatriptan	DM7RE8P	Moderate	Additive CNS depression effects by the combination of Tizanidine and Frovatriptan.	Migraine [8A80]	[12]
Rizatriptan	DMDJMA3	Moderate	Additive CNS depression effects by the combination of Tizanidine and Rizatriptan.	Migraine [8A80]	[12]
Naratriptan	DMO50U2	Moderate	Additive CNS depression effects by the combination of Tizanidine and Naratriptan.	Migraine [8A80]	[12]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Tizanidine and Lasmiditan.	Migraine [8A80]	[40]
Exjade	DMHPRWG	Major	Decreased metabolism of Tizanidine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[17]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Tizanidine and Flibanserin.	Mood disorder [6A60-6E23]	[41]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Panobinostat.	Multiple myeloma [2A83]	[42]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Tizanidine and Thalidomide.	Multiple myeloma [2A83]	[43]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Siponimod.	Multiple sclerosis [8A40]	[14]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Fingolimod.	Multiple sclerosis [8A40]	[8]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Tizanidine and Ozanimod.	Multiple sclerosis [8A40]	[44]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Romidepsin.	Mycosis fungoides [2B01]	[8]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[8]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[45]
Phenindamine	DMDTC7R	Moderate	Additive CNS depression effects by the combination of Tizanidine and Phenindamine.	Nasopharyngitis [CA00]	[12]
Dimenhydrinate	DM264B3	Moderate	Additive CNS depression effects by the combination of Tizanidine and Dimenhydrinate.	Nausea/vomiting [MD90]	[12]
Promethazine	DM6I5GR	Moderate	Additive CNS depression effects by the combination of Tizanidine and Promethazine.	Nausea/vomiting [MD90]	[12]
Cyclizine	DM9G7BS	Moderate	Additive CNS depression effects by the combination of Tizanidine and Cyclizine.	Nausea/vomiting [MD90]	[12]
Metoclopramide	DMFA5MY	Moderate	Additive CNS depression effects by the combination of Tizanidine and Metoclopramide.	Nausea/vomiting [MD90]	[12]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Granisetron.	Nausea/vomiting [MD90]	[8]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Dolasetron.	Nausea/vomiting [MD90]	[8]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Ondansetron.	Nausea/vomiting [MD90]	[8]
E-2007	DMJDYNQ	Moderate	Additive CNS depression effects by the combination of Tizanidine and E-2007.	Neuropathy [8C0Z]	[12]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Entrectinib.	Non-small cell lung cancer [2C25]	[14]
Sibutramine	DMFJTDI	Moderate	Additive CNS depression effects by the combination of Tizanidine and Sibutramine.	Obesity [5B80-5B81]	[12]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[9]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Lofexidine.	Opioid use disorder [6C43]	[8]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Tizanidine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[14]
Rucaparib	DM9PVX8	Major	Decreased metabolism of Tizanidine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[17]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Tizanidine and Oxymorphone.	Pain [MG30-MG3Z]	[11]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Tizanidine and Levorphanol.	Pain [MG30-MG3Z]	[11]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Tizanidine and Dezocine.	Pain [MG30-MG3Z]	[11]
Flavoxate	DMKV4NL	Moderate	Additive CNS depression effects by the combination of Tizanidine and Flavoxate.	Pain [MG30-MG3Z]	[12]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Tizanidine and Nalbuphine.	Pain [MG30-MG3Z]	[11]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Tizanidine and Buprenorphine.	Pain [MG30-MG3Z]	[46]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Tizanidine and Hydrocodone.	Pain [MG30-MG3Z]	[11]
Ziconotide	DMSLJP4	Moderate	Additive CNS depression effects by the combination of Tizanidine and Ziconotide.	Pain [MG30-MG3Z]	[12]
Thiabendazole	DM7YCK3	Major	Decreased metabolism of Tizanidine caused by Thiabendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[17]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Triclabendazole.	Parasitic worm infestation [1F90]	[8]
Pergolide	DM14MAE	Moderate	Additive CNS depression effects by the combination of Tizanidine and Pergolide.	Parkinsonism [8A00]	[12]
Opicapone	DM1BKA6	Moderate	Additive CNS depression effects by the combination of Tizanidine and Opicapone.	Parkinsonism [8A00]	[12]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Tizanidine and Biperiden.	Parkinsonism [8A00]	[12]
Levodopa	DMN3E57	Moderate	Additive CNS depression effects by the combination of Tizanidine and Levodopa.	Parkinsonism [8A00]	[12]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Pimavanserin.	Parkinsonism [8A00]	[47]
Bromocriptine	DMVE3TK	Moderate	Additive CNS depression effects by the combination of Tizanidine and Bromocriptine.	Parkinsonism [8A00]	[12]
Orphenadrine	DMW542E	Moderate	Additive CNS depression effects by the combination of Tizanidine and Orphenadrine.	Parkinsonism [8A00]	[12]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tizanidine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Famotidine	DMRL3AB	Major	Decreased metabolism of Tizanidine caused by Famotidine mediated inhibition of CYP450 enzyme.	Peptic ulcer [DA61]	[17]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[49]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Lefamulin.	Pneumonia [CA40]	[50]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Ritodrine.	Preterm labour/delivery [JB00]	[16]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Degarelix.	Prostate cancer [2C82]	[9]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and ABIRATERONE.	Prostate cancer [2C82]	[9]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Enzalutamide.	Prostate cancer [2C82]	[9]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Relugolix.	Prostate cancer [2C82]	[9]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Bicalutamide.	Prostate cancer [2C82]	[9]
Levomepromazine	DMIKFEL	Moderate	Additive CNS depression effects by the combination of Tizanidine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[12]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[51]
Neupro	DMHEAB1	Moderate	Additive CNS depression effects by the combination of Tizanidine and Neupro.	Restless legs syndrome [7A80]	[12]
Quetiapine	DM1N62C	Moderate	Additive CNS depression effects by the combination of Tizanidine and Quetiapine.	Schizophrenia [6A20]	[12]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Mesoridazine.	Schizophrenia [6A20]	[8]
Aripiprazole	DM3NUMH	Moderate	Additive CNS depression effects by the combination of Tizanidine and Aripiprazole.	Schizophrenia [6A20]	[12]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Iloperidone.	Schizophrenia [6A20]	[8]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Paliperidone.	Schizophrenia [6A20]	[8]
Perphenazine	DMA4MRX	Moderate	Additive CNS depression effects by the combination of Tizanidine and Perphenazine.	Schizophrenia [6A20]	[12]
Molindone	DMAH70G	Moderate	Additive CNS depression effects by the combination of Tizanidine and Molindone.	Schizophrenia [6A20]	[12]
Thiothixene	DMDINC4	Moderate	Additive CNS depression effects by the combination of Tizanidine and Thiothixene.	Schizophrenia [6A20]	[12]
Trifluoperazine	DMKBYWI	Moderate	Additive CNS depression effects by the combination of Tizanidine and Trifluoperazine.	Schizophrenia [6A20]	[12]
Risperidone	DMN6DXL	Moderate	Additive CNS depression effects by the combination of Tizanidine and Risperidone.	Schizophrenia [6A20]	[12]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Amisulpride.	Schizophrenia [6A20]	[52]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Asenapine.	Schizophrenia [6A20]	[8]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Pimozide.	Schizophrenia [6A20]	[9]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Tizanidine and Fentanyl.	Sensation disturbance [MB40]	[11]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Tizanidine and Sufentanil.	Sensation disturbance [MB40]	[11]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[8]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Tizanidine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[9]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Tizanidine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[8]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[8]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[8]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Pitolisant.	Somnolence [MG42]	[8]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[8]
Disulfiram	DMCL2OK	Moderate	Additive CNS depression effects by the combination of Tizanidine and Disulfiram.	Substance abuse [6C40]	[12]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Tizanidine and Naltrexone.	Substance abuse [6C40]	[53]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Tizanidine and Cabozantinib.	Thyroid cancer [2D10]	[9]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Tizanidine and Tacrolimus.	Transplant rejection [NE84]	[8]
Nalidixic acid	DMRM0JV	Major	Decreased metabolism of Tizanidine caused by Nalidixic acid mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[17]
Chlorpheniramine	DM5URA2	Moderate	Additive CNS depression effects by the combination of Tizanidine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[12]
Methdilazine	DMAUHQX	Moderate	Additive CNS depression effects by the combination of Tizanidine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[12]
Carbinoxamine	DMCT31R	Moderate	Additive CNS depression effects by the combination of Tizanidine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[12]
Trimeprazine	DMEMV9D	Moderate	Additive CNS depression effects by the combination of Tizanidine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Brompheniramine	DMFOVSD	Moderate	Additive CNS depression effects by the combination of Tizanidine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[12]
Acrivastine	DMTIGA0	Moderate	Additive CNS depression effects by the combination of Tizanidine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[12]
Azatadine	DMZ80SB	Moderate	Additive CNS depression effects by the combination of Tizanidine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[12]
Propafenone	DMPIBJK	Major	Decreased metabolism of Tizanidine caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[17]
Amiodarone	DMUTEX3	Major	Decreased metabolism of Tizanidine caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[17]
Aciclovir	DMYLOVR	Major	Decreased metabolism of Tizanidine caused by Aciclovir mediated inhibition of CYP450 enzyme.	Virus infection [1A24-1D9Z]	[17]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Ethyl acrylate	E00191	8821	Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tizanidine 2 mg tablet	2 mg	Oral Tablet	Oral
Tizanidine 4 mg tablet	4 mg	Oral Tablet	Oral
Tizanidine Hydrochloride eq 2mg base tablet	eq 2mg base	Tablet	Oral
Tizanidine 2 mg capsule	2 mg	Oral Capsule	Oral
Tizanidine 4 mg capsule	4 mg	Oral Capsule	Oral
Tizanidine 6 mg capsule	6 mg	Oral Capsule	Oral
Tizanidine Hydrochloride eq 4mg base tablet	eq 4mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7308).
• [2] BDDCS applied to over 900 drugs
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [6] Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
• [7] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [8] Canadian Pharmacists Association.
• [9] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [10] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [11] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [12] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
• [13] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [14] Cerner Multum, Inc. "Australian Product Information.".
• [15] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [16] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [17] Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
• [18] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [19] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [20] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [21] Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2." Clin Pharmacol Ther 78 (2005): 400-11. [PMID: 16198659]
• [22] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [23] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [24] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [25] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [26] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [27] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [28] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [29] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [30] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [31] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [32] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [33] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [34] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [35] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [36] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [37] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [38] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [39] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [40] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [41] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [42] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [43] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [44] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [45] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [46] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [47] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [48] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [49] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [50] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [51] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [52] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [53] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.